HEALTH PROFESSIONAL · SOURCE READING

Treatment Options for High-Risk Neuroblastoma

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of High-Risk Neuroblastoma

Outcomes for patients with high-risk neuroblastoma remain poor despite recent improvements in survival in randomized trials.

Treatment options for high-risk neuroblastoma typically include the following:

A regimen of chemotherapy, surgery, tandem cycles of myeloablative therapy and hematopoietic stem cell transplant (HSCT), radiation therapy, and dinutuximab, with granulocyte-macrophage colony-stimulating factor (GM-CSF) and isotretinoin.

Source links and citations

A regimen of chemotherapy, surgery, tandem cycles of myeloablative therapy and hematopoietic stem cell transplant (HSCT), radiation therapy, and dinutuximab, with granulocyte-macrophage colony-stimulating factor (GM-CSF) and isotretinoin

Continue within this section

Chemotherapy, surgery, tandem cycles of myeloablative therapy and HSCT, radiation therapy, and dinutuximab, with GM-CSF and isotretinoin →

Preserved source evidence · Not medical advice